ANALYSIS OF GENETIC ALTERATIONS IN RENAL CELL CARCINOMA.

我们已经证明，在肾癌中观察到了基因组印迹的改变。然而，我们没有发现肾癌的表观遗传学异常改变与其生物学特性之间的关系。CPT-11对人肾癌裸鼠移植瘤有较强的抗肿瘤作用。CPT-11有望成为未来治疗肾癌的新候选药物。白介素7增强了白介素2诱导的淋巴因子激活的杀伤活性，对自体人肾细胞癌有抑制作用。这种联合疗法在治疗肾癌方面的临床应用已经得到证明。我们的回顾性研究忽略了白介素2对脑转移的易感性。在凋亡相关基因方面，肾癌细胞表达Fas，抗Fas激动型抗体显示细胞发生凋亡。此外，干扰素-β还促进了这种细胞的凋亡。在体内实验中，转Fas配体的小鼠肾癌细胞表现出比对照癌细胞更快的生长，可能是由于逃避T细胞的攻击。肾癌患者血清中检测到较高水平的可溶性Fas。这可能是临床有用的转移或复发的检测。

We have already demonstrated that alteration of genomic imprinting was observed in renal cancer. However, we could not detect the relationship between abnormal epigenetic changes and biological characteristics of renal cancer. CPT-11 showed strong antitumor effect against human renal cancer heterotransplanted in nude mice. CPT-11 can be a new candidate as a therapeutic drug for renal cell carcinoma in the future. Enhancement of interleukin 2-induced lymphokine-activated killer activity by interleukin 7 has been shown against autologous human renal cell carcinoma. Clinical usefulness of this combination therapy against renal cancer has been demonstrated. Susceptibility of brain metastasis by interleukin 2 was neglected by our retrospective study. In terms of apoptosis-related genes, renal cancer cells expressed Fas and showed apoptosis by anti-Fas agonistic antibody. Moreover, this apoptosis was enhanced by interferon-_. In vivo experiments, Fas ligand-transfected mouse renal cancer cells showed more rapid growth than the control cancer cells, probably due to the evasion from T-cell attack. Soluble Fas was detected in high level in the serum from patients with renal cell carcinoma. This may be clinically useful for detecting metastasis or recurrence.